Combotope Therapeutics ApS: Financial statements 2025
CVR: 44308266
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Combotope Therapeutics ApS (CVR 44308266) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -633,359 and a net result of DKK -934,394. Equity in the 2025 report amounted to DKK 1,070,294. The solvency ratio was 98.3%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -633,359
- Profit/Loss
- DKK -934,394
- Equity
- DKK 1,070,294
- Total Assets
- DKK 1,088,869
- Employees
- 1
Official annual report
How creditworthy is Combotope Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Combotope Therapeutics ApS has published its interim report for the period September 14, 2023 – December 31, 2024.
About Combotope Therapeutics ApS
Combotope Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Klas Ola Blixt and Søren Nyboe Jakobsen. The company is owned by MOLIOR HOLDING ApS and Kolab Holding ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -633,359 and a net result of DKK -934,394. Equity in the 2025 report amounted to DKK 1,070,294.